These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36933006)

  • 1. Venetoclax in acute myeloid leukemia.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Investig Drugs; 2023 Apr; 32(4):271-276. PubMed ID: 36933006
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 3. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
    Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
    Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
    Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax in AML: Where We Are and Where We Are Headed.
    Pollyea DA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax.
    Konopleva MY
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101251. PubMed ID: 33762105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
    Aldoss I; Marcucci G
    Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
    [No Abstract]   [Full Text] [Related]  

  • 8. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
    Jain P; Mims AS
    Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
    [No Abstract]   [Full Text] [Related]  

  • 9. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Gangat N; Tefferi A
    Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylating agents with venetoclax: have we discovered the holy grail?
    Gutman JA; Pollyea DA
    Curr Opin Hematol; 2020 Mar; 27(2):76-80. PubMed ID: 31895103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?
    Foran JM
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101335. PubMed ID: 34865692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
    Ball BJ; Arslan S; Koller P; Ngo D; Afkhami M; Salhotra A; Al-Malki M; Aribi A; Ali H; Sandhu K; Otoukesh S; Amanam I; Pourhassan H; Artz A; Curtin P; Stein A; Nakamura R; Marcucci G; Smith E; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Dec; 63(13):3232-3236. PubMed ID: 36089918
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
    Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
    [No Abstract]   [Full Text] [Related]  

  • 14. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 15. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.
    Vazquez R; Breal C; Zalmai L; Friedrich C; Almire C; Contejean A; Barreau S; Grignano E; Willems L; Deau-Fischer B; Franchi P; Vignon M; Decroocq J; Birsen R; Goldwirt L; Kaltenbach S; Couronne L; Fontenay M; Kosmider O; Bouscary D; Chapuis N
    Blood Cancer J; 2021 Mar; 11(3):62. PubMed ID: 33741892
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax and acute myeloid leukaemia: an expanding new frontier.
    Sahasrabudhe KD; Mims AS
    Lancet Haematol; 2022 Jun; 9(6):e387-e389. PubMed ID: 35512724
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
    Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
    Naka R; Kondo T; Nishikubo M; Muranushi H; Ueda Y; Oka T; Wada F; Kanda J; Yamamoto S; Watanabe M; Okada S; Imada K; Nakabo Y; Mizutani Y; Nannya Y; Ogawa S; Ishikawa T
    Am J Hematol; 2023 Sep; 98(9):E251-E254. PubMed ID: 37381699
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.